JLE

Hépato-Gastro & Oncologie Digestive

MENU

The seven mistakes not to do inoeso-gastric cancer Volume 26, supplement 2, Novembre 2019

Authors
1 CHU de Rouen, Service d’hépato-gastroentérologie, 76000 Rouen
2 Normandie Univ, UNIROUEN, Inserm1245, IRON group
* Correspondance

Esophageal and gastric cancers represent more than 10,000 new cases per year in France. The TNCD (National Thesaurus of Digestive Oncology) is a French work group gathering many learned societies involved in gastro-intestinal cancers (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR (SIAD and FRI) and SNCP). It provides specific recommendations about management of oesogastric cancers, through two separate chapters. Despite existing recommendations, many empirical practices persist, based on intuitive ideas, and not confirmed by evidence-based medicine. The main seven mistakes not to do in oesogastric cancers are : to put an esophageal stent before chemoradiotherapy, to define HER2 status on a small number of biopsies, to compromise cancer resection by deteriorating the general condition under chemotherapy in localised gastric adenocarcinoma, not to search Helicobacter Pylori infection in relatives of patient with a gastric cancer, not to perform perioperative chemotherapy in gastric signet ring cell adenocarcinoma, to use HER2 inhibitors in second-line treatment of metastatic cancers, not to look for MSI status in gastric adenocarcinoma. Each point will be approached in a concise and well-reasoned manner, as some of these mistakes correspond to ideas that are widespread in the medical community.

Licence This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License